Immune checkpoint inhibitors (ICIs), as represented by anti-programmed cell death (ligand) 1 [anti-PD(L)1] therapy, have been widely administered as the standard therapy for NSCLC without driver gene mutation. The gene discussed is CD274; the disease is non-small cell lung carcinoma.